FDA approves Tecentriq in second-line NSCLC

12:39 EDT 18 Oct 2016 | BioCentury

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved PD-L1 inhibitor Tecentriq atezolizumab to treat non-small cell lung cancer in patients whose disease has progressed following platinum-containing chemotherapy, and with disease progression following treatment with a targeted therapy if their tumors have EGFR or anaplastic lymphoma kinase (ALK) mutations.

In September, Genentech said Tecentriq met the co-primary endpoints of the Phase III OAK study to treat NSCLC (see BioCentury Extra, Sept. 1).

PD-1 inhibitors Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) and Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) also have FDA approval in second-line NSCLC. Keytruda is approved only for patients who express PD-L1. Tecentriq also has accelerated approval from FDA to treat urothelial carcinoma.

Original Article: FDA approves Tecentriq in second-line NSCLC


More From BioPortfolio on "FDA approves Tecentriq in second-line NSCLC"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...